Stockholders' Equity | 9 Months Ended |
Dec. 31, 2013 |
Stockholders' Equity [Abstract] | ' |
Stockholders' Equity | ' |
Note 11. |
Stockholders' Equity |
|
Capital Stock |
|
Preferred Stock |
|
We are authorized to issue up to 10,000,000 shares of preferred stock, $.0001 par value per share. Our board of directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of the shares of preferred stock in series, and by filing a certificate pursuant to the applicable law of the state of Florida, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions thereof. No shares of preferred stock were issued or outstanding at December 31, 2013 and March 31, 2013, respectively. |
|
Common Stock |
|
At December 31, 2013 and March 31, 2013, we were authorized to issue up to 750,000,000 shares of common stock, $.0001 par value per share. |
|
At December 31, 2013 and March 31, 2013, the Company had 71,741,250 and 71,282,066 shares issued and outstanding, respectively. Holders are entitled to one vote for each share of common stock (or its equivalent). |
|
Share Issuances |
|
Common Stock and Warrants |
|
On July 19, 2013, the Company issued 142,500 shares of common stock to National Securities Corporation in consideration for consulting and advisory services provided by National Securities Corporation under an advisory services agreement dated August 14, 2012 in connection with the eDiets merger. The $82,650 was recorded as an expense and additional paid-in capital during fiscal year ended March 31, 2013. |
|
On July 19, 2013, the Company issued an aggregate of 316,268 shares of common stock to the seller of Seen On TV, LLC, in accordance with the anti-dilution protection provisions contained in the June 28, 2012 Seen On TV, LLC asset purchase agreement. |
|
On November 19, 2012, the Company entered into a licensing and endorsement agreement with Eight Entertainment, LLC furnishing celebrity endorsement services. The agreement is for a 24-month term and provides for the celebrity eDiets endorsements, advertising and promotion programs. In consideration the Company agreed to a one-time payment of $250,000 and the issuance of warrants to purchase up to 6,500,000 shares of common stock as follows: |
|
| | | | | | | | | | | | | |
Issuance | | Number of Shares | | Exercise Price | | Date of Issuance | | | | | | | |
1 | | 1,500,000 | | $0.01 | | Within 10 days of effectiveness | | | | | | | |
2 | | 1,250,000 | | $0.25 | | 3 months from agreement | | | | | | | |
3 | | 750,000 | | $0.50 | | 12 months from agreement | | | | | | | |
4 | | 1,000,000 | | $0.75 | | 16 months from agreement | | | | | | | |
5 | | 1,000,000 | | $1.00 | | 20 months from agreement | | | | | | | |
6 | | 1,000,000 | | $2.00 | | 24 months from agreement | | | | | | | |
| | 6,500,000 | | | | | | | | | | | |
|
The actual number of warrants to be granted under the agreement was subject to adjustment downward up to 50%, based upon certain performance goals being achieved relating to weight-loss. These provisions constitute a performance commitment within the meaning of ASC 505 - Equity. In accordance with ASC 505 - Equity, when equity instruments are issued to non-employees in exchange for the receipt of goods or services the equity instruments are measured at fair value at the earlier of the date at which a commitment for performance by the counterparty to earn the equity instruments is reached or the date at which the counterparty's performance is complete. The agreement does not contain a sufficiently large disincentive for nonperformance as forfeiture of the equity instrument is the sole remedy in the event of nonperformance. Therefore, a final measurement date will not be established until performance is complete and ASC 505 - Equity requires the recognition of expense from the transaction be measured at the then-current lowest aggregate fair value at each reporting period with changes in those lowest aggregate fair values between the reporting periods recognized in earnings. The first of two performance goals was met during March 2013 reducing the potential adjustment downward to 25%. On May 15, 2013, the second performance goal was not achieved and warrants to purchase 1,625,000 shares of common stock exercisable at prices from $0.01 to $2.00 per share were forfeited. |
|
The related campaign talent costs are being recorded in selling and marketing expenses over the performance period of 24 months. The assumptions used at the initial valuation date, November 19, 2012, and December 31, 2013, were as follows: |
|
| | | | | | | | | | | | | |
| | Lowest Aggregate Fair Value | | | | | | | | | |
| | Initial Valuation | | 31-Dec-13 | | | | | | | | | |
| | | | | | | | | | | | | |
Number of shares underlying warrants | | 3,250,000 | | 4,875,000 | | | | | | | | | |
Exercise prices | | $0.01 - $2.00 | | $0.01 - $2.00 | | | | | | | | | |
Volatility | | 174.00% | | 149.70% | | | | | | | | | |
Risk-free interest rate | | 0.33% | | 0.38% | | | | | | | | | |
Expected dividend yield | | 0.00% | | 0.00% | | | | | | | | | |
Expected warrant life (years) | | 3 | | 1.9 | | | | | | | | | |
|
For the three month and nine month periods ending December 31, 2013, the Company recognized marketing expense or expense (reduction) of approximately $(120,000) and $(114,000), respectively, attributable to warrants issued and approximately $31,000 and $94,000, respectively, attributable to the $250,000 cash component paid. |
|
The Company recognized marketing expense under this agreement of approximately $150,000, including approximately $136,000 attributable to the warrants issued and approximately $14,000 attributable to the cash component for the three and nine month periods ending December 31, 2012. |
|
A summary of warrants outstanding at December 31, 2013, is as follows: |
|
Summary of Warrants Outstanding |
|
| | | | | | | | | | | | | |
Warrant Description | | Number of | | Exercise | | Expiration Dates | | | | | | | |
Warrants (A) | Prices | | | | | | | |
| | | | | | | | | | | | | |
2010 Other Placements | | 975,000 | | $3.00-$10.00 | | January 13, 2014 - January 24, 2014 | | | | | | | |
2011 Convertible Notes | | 431,251 | | $3.00-$10.00 | | 11-Apr-14 | | | | | | | |
2011 Private Placement | | 672,750 | | $3.00-$10.00 | | May 27, 2014 - June 15, 2014 | | | | | | | |
2011 Bridge Warrant | | 8,789,064 | | $0.64 | | 29-Aug-14 | | | | | | | |
2011 Bridge Warrant Placement Agent | | 1,165,875 | | $0.64 | | 29-Aug-14 | | | | | | | |
2011 Unit Offering | | 33,277,837 | (B) | $0.59 | | 28-Oct-16 | | | | | | | |
2011 Unit Offering Placement Agent | | 4,726,891 | (B) | $0.59 | | 28-Oct-16 | | | | | | | |
2010 Other Placements | | 412,500 | | $0.64-$3.15 | | June 1, 2014 - June 22, 2015 | | | | | | | |
2012 Bridge Warrant | | 1,137,735 | (B) | $0.77 | | September 7, 2015 - September 20, 2015 | | | | | | | |
2012 Bridge Warrant Placement Agent | | 227,546 | (B) | $0.77 | | 7-Sep-15 | | | | | | | |
2012 Unit Offering | | 6,300,213 | (B) | $0.80 | | 14-Nov-15 | | | | | | | |
2012 Unit Offering Placement Agent | | 1,561,544 | (B) | $0.70-$0.80 | | 14-Nov-17 | | | | | | | |
2012 Talent Compensation | | 4,875,000 | | $0.01-$2.00 | | 19-Nov-15 | | | | | | | |
2013 Merger related notes converted | | 494,328 | (B) | $0.80 | | 14-Nov-15 | | | | | | | |
2013 eDiets Warrants | | 910,835 | | $1.40-$4.74 | | February 7, 2014 - September 11, 2019 | | | | | | | |
| | 65,958,369 | | | | | | | | | | | |
------- |
(A) |
All warrants reflect post anti-dilution and repricing provisions applied. |
(B) |
Subject to potential further ant-dilution and repricing adjustment (See Note 7). |
|
Equity Compensation Plans |
|
In May 2010, the Company adopted its 2010 Executive Equity Incentive Plan and 2010 Non Executive Equity Incentive Plan (collectively, the "2010 Plans") and granted 600,000 options and 450,000 options, respectively. |
|
The fair value of each option is estimated on the date of grant using the Black Scholes options pricing model using the assumptions established at that time. |
|
On June 4, 2012, the Company issued 30,000 options to a direct response consultant. The fair value of the options granted was estimated on the date of grant using the Black Scholes options pricing model using the assumptions established at that time. The following table includes the assumptions used in valuing this grant: |
|
| | | | | | | | | | | | | |
Number of shares underlying the options | | | 30,000 | | | | | | | | | | |
Exercise price | | | $0.87 | | | | | | | | | | |
Volatility | | | 185 | % | | | | | | | | | |
Risk-free interest rate | | | 0.68 | % | | | | | | | | | |
Expected dividend yield | | | 0 | % | | | | | | | | | |
Expected option life (years) | | | 5 | | | | | | | | | | |
|
As the options vested upon grant, the entire fair value of $25,100 was charged to stock-based compensation immediately and is included in general and administrative expenses. |
|
On September 24, 2012, the Company's board of directors adopted the 2013 Equity Compensation Plan (the "2013 Plan" and, together with the 2010 Plans, the "Plans") with terms similar to the previously adopted 2010 Plans. The 2013 Plan authorized the issuance of up to 3,000,000 options to purchase common stock. The 2013 Plan was modified in March 2013 authorizing the issuance of up to 6,000,000 options. On May 6, 2013, the 2013 Plan was further modified, increasing the shares of common stock reserved for issuance under such plan to 9,000,000 shares. |
|
On December 15, 2012, the compensation committee granted 2,075,000 options from the remaining available options under the Plans. The options were granted to 17 employees and directors of the Company. The options granted vest at 20% per year over a five-year period and expire ten years from grant date. The fair value of the options granted was estimated on the grant date using the Black Scholes options pricing model using the assumptions established at that time. The following table includes the assumptions used in valuing this grant: |
|
| | | | | | | | | | | | | |
Number of shares underlying the options | | | 2,075,000 | | | | | | | | | | |
Exercise price | | | $0.68 | | | | | | | | | | |
Volatility | | | 177 | % | | | | | | | | | |
Risk-free interest rate | | | 1.18 | % | | | | | | | | | |
Expected dividend yield | | | 0 | % | | | | | | | | | |
Expected option life (years) | | | 7 | | | | | | | | | | |
|
On May 2, 2013, effective May 1, 2013, we entered into an employment agreement with Mr. Ronald C. Pruett Jr. to serve as our chief executive officer. As a component of his compensation package the board of directors approved an option grant to purchase 425,000 shares (the "First Option Grant") of our common stock and a second option grant to purchase 2,625,000 shares (the "Second Option Grant") of our common stock. The First Option Grant vested on the grant date, May 6, 2013, and has a per share exercise price equal to $0.35, the average of the high bid and low asked prices of our common stock on the OTC Bulletin Board on the trading day immediately preceding the grant date. The Second Option Grant has a per share exercise price equal to $0.70. The Second Option Grant vests in four equal tranches on May 6, 2013, May 1, 2014, November 1, 2014 and May 1, 2015. Provided that the agreement has not been terminated, on December 31, 2013, Mr. Pruett became entitled to receive subsequent grants of stock and options, at the compensation committee's discretion, with an aggregate value of at least $918,750, vesting in four equal tranches on the grant date, May 1, 2014, November 1, 2014 and May 1, 2015. As of February 10, 2014, Mr. Pruett was not granted any additional stock options. If Mr. Pruett's employment is terminated for any reason, other than by the Company for cause or by Mr. Pruett in the absence of good reason, he shall be entitled to certain compensation and benefits as provided under the agreement. The following table includes the assumptions used in valuing this grant: |
|
| | | | | | | | | | | | | |
Number of shares underlying the option | 425,000 | | | 2,625,000 | | | | | | | | | |
Exercise price | $0.35 | | | $0.70 | | | | | | | | | |
Volatility | 137 | % | | 137 | % | | | | | | | | |
Risk-free interest rate | 1.19 | % | | 1.19 | % | | | | | | | | |
Expected dividend yield | 0 | % | | 0 | % | | | | | | | | |
Expected option life (years) | 7 | | | 7 | | | | | | | | | |
|
On August 1, 2013, the Company issued 500,000 stock options to Henrik Sandell to serve as the Company's chief operating officer. The fair value of the options granted was estimated on the date of grant using the Black Scholes option pricing model using the assumptions established at that time. The following table includes the assumptions used in valuing this grant: |
|
| | | | | | | | | | | | | |
Number of shares underlying the options | | | 500,000 | | | | | | | | | | |
Exercise price | | | $0.70 | | | | | | | | | | |
Volatility | | | 159.03 | % | | | | | | | | | |
Risk-free interest rate | | | 2.15 | % | | | | | | | | | |
Expected dividend yield | | | 0 | % | | | | | | | | | |
Expected option life (years) | | | 7 | | | | | | | | | | |
|
The grant provided that 125,000 options vested upon grant according, $22,250, the fair value of the vested component, was charged to stock based compensation immediately and is included in general and administrative expense. |
|
Mr. Sandell's options vest under the following schedule: |
|
| | | | | | | | | | | | | |
Percent of Grant | | Vesting Date | | | | | | | | | | |
| | | | | | | | | | | | |
25% | | 1-Aug-13 | | | | | | | | | | |
25% | | 1-May-14 | | | | | | | | | | |
25% | | 1-Nov-14 | | | | | | | | | | |
25% | | 1-May-15 | | | | | | | | | | |
|
Stock based compensation for the three month and nine month periods ending December 31, 2013 was approximately $186,000 and $803,000, respectively. Stock based compensation for the three month and nine month periods ending December 31, 2012 was approximately $175,000 and $310,000, respectively. Stock based compensation for all periods presented are included in general and administration expenses, in the accompanying condensed consolidated statements of operations. |
|
Information related to options granted under our option plans at December 31, 2013 and, 2012 and activity for each of the nine months then ended is as follows: |
|
| | | | | | | | | | | | | |
| | Shares | | Weighted | | Weighted Average | | Aggregate | |
Average | Remaining | Intrinsic Value |
Exercise | Contractual Life | |
Price | (Years) | |
Outstanding at April 1, 2013 | | | 5,933,708 | (A) | $ | 2.32 | | | 6.55 | | $ | 44,475 | |
Granted | | | 3,550,000 | | | 0.66 | | | - | | | - | |
Exercised | | | - | | | - | | | - | | | - | |
Forfeited | | | (1,461,357 | ) | | 5.97 | | | - | | | - | |
Expired | | | (29,388 | ) | | 0.83 | | | - | | | - | |
Outstanding at December 31, 2013 | | | 7,992,963 | | $ | 1.39 | | | 7.35 | | $ | - | |
Exercisable at December 31, 2013 | | | 4,756,713 | | $ | 2.52 | | | 6.03 | | $ | - | |
|
| | | | | | | | | | | | | |
| | Shares | | Weighted | | Weighted Average | | Aggregate | |
Average | Remaining | Intrinsic Value |
Exercise | Contractual Life | |
Price | (Years) | |
Outstanding at April 1, 2012 | | | 1,025,000 | | $ | 1.31 | | | - | | $ | - | |
Granted | | | 2,105,000 | | | 0.68 | | | - | | | - | |
Exercised | | | - | | | - | | | - | | | - | |
Forfeited | | | (12,500 | ) | | 0.96 | | | - | | | - | |
Expired | | | - | | | - | | | - | | | - | |
Outstanding at December 31, 2012 | | | 3,117,500 | | $ | 0.89 | | | 7.67 | | $ | - | |
Exercisable at December 31, 2012 | | | 880,000 | | $ | 1.37 | | | 3.02 | | $ | - | |
------- |
(A) |
Includes 2,816,208 eDiets acquisition adjusted replacement options. |
|
The weighted average grant date fair value of unvested options at December 31, 2013, was approximately $1,256,000 and will be expensed over a weighted average period of 6.33 years. |
|
As of December 31, 2013, there were 4,822,500 options available for further issuance under the Plans. |
|
In addition, under the provisions of ASC 805-Business Combinations, the Company recognized as stock-based compensation the difference in fair value between the eDiets options outstanding at the acquisition date and the replacement ASTV options granted. The fair value of the eDiets' options replaced of $604,218 was recorded as consideration transferred in the acquisition. The excess fair value of the ASTV replacement options over the fair value of the eDiets options was recognized as compensation cost in the year ended March 31, 2013 since substantially all of the options were fully vested. Accordingly, the Company recorded $694,000 in stock-based compensation in March 2013. |
|
No tax benefits are attributable to our share based compensation expense recorded in the accompanying financial statements because we are in a net operating loss position and a full valuation allowance is maintained for all net deferred tax assets. For stock options, the amount of the tax deductions is generally the excess of the fair market value of our shares of common stock over the exercise price of the stock options at the date of exercise. |
|
In the event of any stock split of our outstanding shares of common stock, the board of directors in its discretion may elect to maintain the stated amount of shares reserved under the Plans without giving effect to such stock split. Subject to the limitation on the aggregate number of shares issuable under the Plans, there is no maximum or minimum number of shares as to which a stock grant or plan option may be granted to any person. Grants under the Plans may either be (i) ISOs, (ii) NSOs (iii) awards of our common stock or (iv) rights to make direct purchases of our common stock which may be subject to certain restrictions. Any option granted under the Plans must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The Plans further provide that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any option holder during any calendar year cannot exceed $100,000. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or the compensation committee, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. |
|
At the effective time of the merger with eDiets, each eDiets option that remained outstanding and unexercised following the effective time was deemed amended and is now exercisable for shares of our common stock. The terms and conditions of the options remained the same, except that the number of shares covered by the option, and the exercise price was adjusted to reflect the exchange ratio of 1.2667. The exercise price per share is now equal to the exercise price prior to the effective time, divided by the exchange ratio. The above discussion reflects options and shares adjusted for the exchange ratio. |